2026年2月3日，中央一号文件《中共中央 国务院关于锚定农业农村现代化 扎实推进乡村全面振兴的意 见》发布，部署扎实推进乡村全面振兴。这是党的十八大以来第14个指导"三农"工作的中央一号文件， 也是"十五五"首个中央一号文件。 《中共中央国务院关于锚定农业农村现代化扎实推进乡村全面振兴的意见》提出，促进"菜篮子"产业提 质增效。坚持农林牧渔并举，推动构建多元化食物供给体系。强化生猪产能综合调控，巩固肉牛、奶牛 产业纾困成果，促进供求平衡、健康发展。多措并举促进乳制品消费。支持发展青贮玉米、苜蓿等饲草 料生产，促进草原畜牧业转型升级。支持设施农业更新改造，稳定发展蔬菜生产，推进深远海养殖和现 代化远洋捕捞，积极发展森林食品和生物农业。严格落实食品安全责任制，强化多部门协同和全链条监 管，严查严惩非法添加和农兽药残留超标等问题。 乳品业相关港股包括：澳优(01717)、H&H国际控股(01112)、蒙牛乳业(02319)、现代牧业(01117)、中国 飞鹤(06186)、优然牧业(09858)、原生态牧业(01431)等。 【大势展望】 现货黄金上涨286.94美元，涨幅6.16%，报4947.04美元/盎司 ...

每经记者｜杨建 每经编辑｜肖芮冬 ｜2026年2月4日 星期三｜ NO.1 2026年中央一号文件：实施农村电商高质量发展工程，推动电商平台下沉赋能 2月3日，中央一号文件《中共中央、国务院关于锚定农业农村现代化扎实推进乡村全面振兴的意见》发 布，意见指出，培育壮大县域富民产业。统筹发展科技农业，推动农村一二三产业深度融合。支持发展 绿色高效种养，推进农产品精深加工，培育农业精品品牌，促进全产业链开发。实施农村电商高质量发 展工程，推动电商平台下沉赋能，加强产地预冷、仓储保鲜、分拣加工等设施建设。规范农产品直播带 货。 2月3日，中国科学院物理研究所与北京大学的联合科研团队在国际上首次利用超导量子模块，实验观测 并人工调控量子多体系统走向混沌前的关键中间状态——"预热化"平台。这一发现为理解并控制复杂的 量子动力学过程打开了新窗口，相关成果日前在线发表于国际学术期刊《自然》。 NO.5 瑞银：存储2028年才有可能出现有意义的供给缓解 2月3日，瑞银分析师团队表示，短期可聚焦于两大堪称垄断的HDD霸主——即希捷与西部数据公司， 可把它们共同当作"存储景气度周期类型短期交易主题"，中长期把超额收益押在Memor ...

在皮肤科治疗中,医生有时会开出一种药膏,有时则会开出两种甚至更多,并嘱咐一起或交替使用。这并非 随意为之,而是一种精妙的治疗策略——联合用药。 联合用药的核心在于通过不同机制的药物协同作用,达到提高疗效、减少副作用、缩短疗程、防止或延 缓耐药性的目的。 荣成市中医院专家强调,联合用药必须严格遵循医嘱。患者需注意用药顺序与间隔时间,例如抗感染药通 常需先于激素使用,而保湿剂应在抗炎药物吸收后再涂抹。治疗期间需密切监测皮肤反应,出现不适及时 复诊。科学的联合用药,配合患者正确的使用与护理,方能实现最佳治疗效果。 (王晓萍) ...

Core Viewpoint - The market showed a rebound today, with the overall index rising after a previous decline, indicating a potential recovery phase in the market [1][4]. Market Performance - The market opened lower but closed higher, returning to a 3.9 star rating [2]. - The small and medium-cap indices, which had previously dropped significantly, saw a notable increase today [4]. - The value style had a strong performance in the past two weeks but has recently corrected, with a slight uptick today [6]. - Growth styles, such as the ChiNext, experienced gains today [7]. - The Hong Kong stock market also saw a slight increase, contrasting with the A-share market [8][9]. Investment Strategies - The active and index combination remains at normal valuation, leading to a pause in subscription [3]. - Some indices have reached high valuation levels, presenting potential profit-taking opportunities [19]. - The company has initiated a phased profit-taking strategy for certain funds, selling 10% of holdings weekly to gradually realize gains [20][22][24]. - Specific funds, such as the CSI 1000 and CSI 500 Low Volatility, have shown significant returns, with profit-taking executed at approximately 71% to 90% gains [22][24]. Fund Management - The company has introduced a new fee structure for advisory services, capping annual fees at 360 yuan regardless of the number of advisory combinations held [19]. - The company continues to promote personal pension fund investments, highlighting the importance of regular contributions for retirement planning [19][16]. Valuation Insights - A valuation table was provided, indicating various indices' price-to-earnings ratios, dividend yields, and return on equity, which can guide investment decisions [17][30]. - The valuation table categorizes indices into different investment stages, with green indicating undervalued, yellow for normal, and red for overvalued [34].

Group 1 - The Indian stock market, which faced the worst performance among emerging markets in 2025, is experiencing renewed optimism following a trade agreement with the U.S. that includes a reduction in tariffs on Indian goods [1][2] - The U.S. will lower the tariff rate on Indian goods from 25% to 18%, effective immediately, while India will stop purchasing Russian oil, which is expected to stabilize the Indian rupee and attract foreign investment back into the market [1][4] - Following the announcement, the Nifty 50 index rose by 2.55% and the Sensex index increased by 2.54%, marking the strongest single-day gains since May of the previous year [1] Group 2 - Despite the high tariffs imposed by the U.S., India's economy has shown resilience, with GDP growth projected at 7.4% for the fiscal year 2025-26, up from 6.5% in the previous year [2] - The Indian rupee appreciated by 1.5% against the dollar, reaching 90.1250, indicating a potential recovery after a year of depreciation [1][3] - The trade agreement is expected to have a positive structural impact on India's economy, enhancing its strategic importance to global investors and improving market sentiment [6] Group 3 - Various sectors related to exports, including automotive, pharmaceuticals, energy, and infrastructure, saw significant gains, with increases exceeding 2% [5] - Analysts predict that 2026 could be a recovery year for the Indian stock market, with firms like Goldman Sachs and HSBC upgrading their ratings on Indian stocks due to recent government reforms [6] - However, concerns remain regarding the attractiveness of Indian equities, as the market's valuation remains high compared to other emerging markets, with a premium of 55% to 60% [7][8]

Group 1 - The core point of the article is that Minsheng Health (301507.SZ) has repurchased a total of 1,252,100 shares, which represents 0.35% of the company's total share capital, as of January 31, 2026 [1] - The shares were repurchased through a dedicated securities account via centralized bidding transactions [1] - The highest transaction price was 15.67 yuan per share, while the lowest was 14.39 yuan per share, with a total payment amounting to 18,904,670.00 yuan (excluding transaction fees) [1]

Group 1 - The core point of the article is that Jiatang (002462.SZ) announced a share transfer agreement with Tongrentang Group, resulting in a change of controlling shareholder and actual controller to the Beijing Municipal Government State-owned Assets Supervision and Administration Commission [1] Group 2 - The agreement involves the transfer of 41.1808 million shares and 41.8764 million shares from Guangda Industrial and Guangda Health to Tongrentang Group [1] - Following the completion of this transaction, the company's stock will resume trading on February 4, 2026 [1]

Group 1: Consumer Sector Overview - Despite macroeconomic uncertainties, the consumer sector is undergoing a deep adjustment phase, with leading companies showing structural resilience and positive signals emerging in several sub-sectors [1] - The investment logic in the consumer sector has shifted from Beta-driven to Alpha-exploration, focusing on leading companies with scale barriers, brand influence, and operational efficiency [1] Group 2: Alcohol Industry - The overall sales of the liquor industry are experiencing a double-digit decline, but Kweichow Moutai is outperforming market expectations, with significant pre-holiday demand and double-digit growth in several key markets [2] - Moutai's traditional channel shipment progress is at 25%, with historical low inventory levels, leading to a steady price recovery to nearly 1700 yuan, confirming the price bottom [2] - The trend of increasing industry concentration continues, with leading brands expected to achieve year-on-year growth despite macroeconomic pressures [2] Group 3: Snack Industry - The bulk snack channel is rapidly replacing traditional retail formats, with a market size exceeding 129.7 billion yuan and a compound annual growth rate of 77.9% from 2019 to 2024 [3] - The market is highly concentrated, with leading brands "Mingming Hen Mang" and "Wancheng" holding over 75% market share, and "Mingming Hen Mang" alone accounting for approximately 43% [3] - The operational efficiency of leading companies is expected to enhance market penetration, benefiting from scale effects and further increasing industry concentration [3] Group 4: Pharmaceutical Industry - The investment opportunities in the pharmaceutical sector are increasingly structural, with the innovative drug industry chain remaining a core focus, particularly in areas like immunotherapy and small nucleic acid technology [4] - The CXO sector is experiencing a steady recovery, with improved overseas biotech financing conditions and a structural rebound in domestic CRO demand [4] - The medical device sector is expected to benefit from recovering hospital demand and improving inventory cycles, with domestic companies likely to gain market share due to expanding procurement policies [5] Group 5: Agriculture and Livestock - The pig farming industry is undergoing capacity reduction, with the number of breeding sows decreasing to 39.61 million by the end of 2025, leading to a potential price recovery supported by seasonal demand [7] - The poultry farming sector is facing tight supply due to previous overseas breeding restrictions, while the yellow feather chicken market is entering a growth phase with low historical breeding costs [7] - The planting sector is benefiting from agricultural cycle rotations and policy support, with the domestic transgenic corn industry expected to expand, favoring leading seed companies with strong R&D capabilities [7]

每经AI快讯，2月3日，港交所文件显示，丹诺医药(苏州)股份有限公司-B向港交所提交上市申请书，联 合保荐人为中信证券和农银国际。 ...

行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 医药生物行业周报 《药品管理法实施条例》全面修订，推 动医药产业创新与监管升级 2026 年 02 月 03 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 《聚焦脑机接口与小核酸药物，JPM 盛会 前奏下医疗布局新浪潮》 2026.01.14 《创新浪潮涌动下，医药板块修复与突破 之路》 证书编号：S1160525080001 相对指数表现 -10% 0% 10% 20% 30% 40% 2025/2 2025/8 2026/2 医药生物 沪深300 相关研究 2025.12.15 《医药生物行业 2025 年三季报财报总结： 业绩分化，医疗设备板块显现拐点》 2025.11.13 告 本周( ...